We analyzed VSTM2L expression in different cancers; the TIMER data across all TCGA tumors showed that compared to corresponding normal tissue, VSTM2L was significantly upregulated in BRCA, KIRP, LUAD, PAAD, PCPG, PRAD, and THCA and downregulated in COAD, GBM, KICH, KIRC, LUSC, STAD, and UCEC (Figure 1C). This evidence concerns the gene VSTM2L and cancer.